Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Farmers Insurance
Harvard Business School
Mallinckrodt
Johnson and Johnson
QuintilesIMS

Generated: September 19, 2019

DrugPatentWatch Database Preview

Patent: 10,016,434

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,016,434
Title:Methods for the treatment of HER2 amplified cancer
Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
Inventor(s): Chen; Jun (San Jose, CA), Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:15/652,470
Patent Claims:see list of patent claims

Details for Patent 10,016,434

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up Pharmacyclics LLC (Sunnyvale, CA) 2033-08-12 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up Pharmacyclics LLC (Sunnyvale, CA) 2033-08-12 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up Pharmacyclics LLC (Sunnyvale, CA) 2033-08-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Argus Health
Cipla
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.